249 related articles for article (PubMed ID: 27787742)
1. [
Kwee SA; Sato MM; Kuang Y; Franke A; Custer L; Miyazaki K; Wong LL
Mol Imaging Biol; 2017 Jun; 19(3):446-455. PubMed ID: 27787742
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomics Associates Molecular Features with
Kwee SA; Tiirikainen M; Sato MM; Acoba JD; Wei R; Jia W; Le Marchand L; Wong LL
Cancer Res; 2019 Apr; 79(7):1696-1704. PubMed ID: 30760520
[TBL] [Abstract][Full Text] [Related]
3. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
Wallace MC; Sek K; Francis RJ; Samuelson S; Ferguson J; Tibballs J; Asad A; Preen DB; MacQuillan G; Garas G; Adams LA; Jeffrey GP
Dig Dis Sci; 2020 Feb; 65(2):647-657. PubMed ID: 31440998
[TBL] [Abstract][Full Text] [Related]
4. PET/CT with
Kwee SA; Wong L; Chan OTM; Kalathil S; Tsai N
Radiology; 2018 Apr; 287(1):294-302. PubMed ID: 29315063
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characteristics distinguishing intrahepatic cholangiocarcinoma: a negative pilot study of (18)F-fluorocholine PET/CT clarified by transcriptomic analysis.
Kwee SA; Okimoto GS; Chan OT; Tiirikainen M; Wong LL
Am J Nucl Med Mol Imaging; 2016; 6(1):73-83. PubMed ID: 27069767
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
[TBL] [Abstract][Full Text] [Related]
8. Arterial Phase 18F-Fluorocholine PET/CT in Hepatocellular Carcinoma.
Legendre A; Collet G; Lahousse H; Aziz AL; Petyt G
Clin Nucl Med; 2019 Feb; 44(2):133-136. PubMed ID: 30516677
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma.
Bieze M; Klümpen HJ; Verheij J; Beuers U; Phoa SS; van Gulik TM; Bennink RJ
Hepatology; 2014 Mar; 59(3):996-1006. PubMed ID: 24123111
[TBL] [Abstract][Full Text] [Related]
10. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
[TBL] [Abstract][Full Text] [Related]
11. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.
Wu HB; Wang QS; Li BY; Li HS; Zhou WL; Wang QY
Clin Nucl Med; 2011 Dec; 36(12):1092-7. PubMed ID: 22064078
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
16. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
17. Utility of [
Kavanaugh G; Williams J; Morris AS; Nickels ML; Walker R; Koglin N; Stephens AW; Washington MK; Geevarghese SK; Liu Q; Ayers D; Shyr Y; Manning HC
Mol Imaging Biol; 2016 Dec; 18(6):924-934. PubMed ID: 27677886
[TBL] [Abstract][Full Text] [Related]
18. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
19. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of [
Jamsek J; Hocevar M; Bergant D; Zaletel K; Rep S; Lezaic L
Ann Nucl Med; 2021 Apr; 35(4):429-437. PubMed ID: 33544320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
